JFAN-1001
/ Zhejiang Jianfeng Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 17, 2025
Zhejiang Jianfeng…announced that its subsidiary Jianfeng Yien Biotechnology has obtained approval from the National Medical Products Administration (NMPA) to begin a clinical trial of JFAN‑1001 Mesylate Capsules in combination with Vinorelbine Tartrate Soft Capsules for patients with advanced non‑squamous non‑small cell lung cancer (NSCLC)
(flcube.com)
- "Approval granted for Phase II trial in China (combined JFAN‑1001 + Vinorelbine)....Phase II Enrollment - Expected to enroll 200‑250 patients across major oncology centers in Hangzhou and Shanghai."
New P2 trial • Lung Non-Squamous Non-Small Cell Cancer
1 to 1
Of
1
Go to page
1